◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BIIB

Biogen Inc (BIIB) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-09-17

Biogen Inc (BIIB) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 7,500 employees. Its market capitalization is roughly $32 billion. In the fiscal year ended 2025-12-31, BIIB reported $9.8B in revenue and $1.3B in net income.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Interactive charts & full statements → Open the BIIB valuation workbench →

BIIB Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$9.9B	$9.8B	$9.7B	$9.8B	$10.2B	$11.0B	$13.4B	$14.4B	$13.5B	$12.3B	$11.4B	$10.8B	$9.7B	$6.9B	$5.5B	$5.0B	$4.7B	$4.4B	$4.1B	$3.2B	$2.7B
Gross Profit	$6.7B	$6.9B	$7.4B	$7.3B	$7.9B	$8.9B	$11.6B	$12.4B	$11.6B	$10.6B	$10.0B	$9.5B	$8.5B	$6.1B	$5.0B	$4.6B	$4.3B	$4.0B	$3.7B	$2.8B	$2.4B
Gross Margin %	67.7%	70.5%	76.1%	74.2%	77.6%	80.8%	86.6%	86.4%	86.5%	86.7%	87.5%	88.5%	87.9%	87.6%	90.1%	90.8%	91.5%	91.3%	90.2%	89.4%	89.8%
Operating Income (EBIT)	$1.3B	$1.9B	$2.5B	$2.1B	$2.9B	$2.8B	$4.6B	$7.0B	$5.9B	$5.3B	$5.2B	$4.9B	$4.0B	$2.5B	$1.8B	$1.7B	$1.2B	$1.3B	$1.2B	$780M	$440M
Operating Margin %	12.8%	19.1%	25.7%	21.3%	28.4%	25.4%	34.2%	49.0%	43.8%	43.5%	45.0%	45.4%	40.9%	36.3%	33.3%	34.2%	26.5%	29.6%	29.6%	24.6%	16.4%
Net Income	$835M	$1.3B	$1.6B	$1.2B	$3.0B	$1.6B	$4.0B	$5.9B	$4.4B	$2.5B	$3.7B	$3.5B	$2.9B	$1.9B	$1.4B	$1.2B	$1.0B	$970M	$783M	$638M	$218M
Net Margin %	8.4%	13.2%	16.9%	11.8%	29.9%	14.2%	29.8%	41.0%	32.9%	20.7%	32.3%	33.0%	30.2%	26.9%	25.0%	24.4%	21.3%	22.2%	19.1%	20.1%	8.1%
EBITDA	$1.7B	$3.1B	$3.0B	$2.4B	$3.5B	$3.9B	$5.1B	$7.7B	$7.0B	$6.6B	$6.3B	$5.6B	$4.6B	$3.0B	$2.2B	$2.1B	$1.6B	$1.8B	$1.7B	$1.3B	$869M
Earnings Per Share (EPS)	$5.65	$8.82	$11.19	$7.97	$20.87	$10.40	$24.80	$31.42	$21.58	$11.92	$16.92	$15.34	$12.37	$7.81	$5.76	$5.04	$3.94	$3.35	$2.65	$1.99	$0.63
Shares Outstanding (M)	149M	147M	146M	146M	146M	150M	161M	187M	205M	213M	219M	231M	237M	238M	240M	245M	255M	289M	295M	320M	345M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIIB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$2.7B	$2.5B	$2.3B	$2.5B	$2.6B	$2.4B	$2.5B	$2.5B
Gross Profit	$1.6B	$1.8B	$1.8B	$1.6B	$1.7B	$1.9B	$1.9B	$1.8B
Gross Margin %	56.9%	73.3%	78.2%	64.3%	64.2%	76.2%	76.2%	74.1%
Operating Income (EBIT)	$318M	$397M	($57M)	$614M	$588M	$733M	$509M	$577M
Operating Margin %	11.6%	16.0%	-2.5%	25.0%	22.2%	30.1%	20.7%	23.4%
Net Income	$98M	$320M	($48M)	$466M	$635M	$240M	$267M	$388M
Net Margin %	3.6%	12.9%	-2.1%	19.0%	24.0%	9.9%	10.9%	15.8%
EBITDA	$78M	$554M	$212M	$827M	$1.1B	$865M	$692M	$714M
Earnings Per Share (EPS)	$0.66	$2.15	$-0.33	$3.17	$4.35	$1.65	$1.83	$2.66
Shares Outstanding (M)	149M	148M	147M	147M	146M	146M	146M	146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIIB Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2.9B	$2.2B	$2.9B	$1.5B	$1.4B	$3.6B	$4.2B	$7.1B	$6.2B	$4.6B	$4.5B	$3.7B	$2.9B	$2.3B	$1.9B	$1.7B	$1.6B	$1.1B	$1.6B	$1.0B	$841M
Capital Expenditures (CapEx)	$182M	$154M	$360M	$311M	$240M	$295M	$552M	$514M	$771M	$867M	$616M	$643M	$288M	$3.5B	$255M	$252M	$173M	$166M	$276M	$284M	$198M
Free Cash Flow (FCF)	$2.7B	$2.1B	$2.5B	$1.2B	$1.1B	$3.3B	$3.7B	$6.6B	$5.4B	$3.7B	$3.9B	$3.1B	$2.7B	($1.2B)	$1.6B	$1.5B	$1.5B	$909M	$1.3B	$737M	$643M
FCF Margin %	27.1%	20.9%	26.0%	12.6%	11.2%	30.5%	27.4%	45.6%	40.3%	30.0%	34.1%	28.5%	27.4%	-16.8%	29.5%	29.2%	30.8%	20.8%	31.4%	23.2%	24.0%
Dividends Paid	—	—	—	—	—	$1M	$5M	—	$36M	$303M	$0M	$5.9B	$54.8B	$66.7B	$67.4B	$27M	$12M	$4M	$987M	$1.5B	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIIB Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$449M	$646M	$512M	$1.3B	$161M	$259M	$761M	$936M
Capital Expenditures (CapEx)	$41M	$51M	$44M	$46M	$17M	$47M	$66M	$130M
Free Cash Flow (FCF)	$408M	$594M	$468M	$1.2B	$144M	$212M	$695M	$806M
FCF Margin %	14.9%	24.0%	20.5%	50.0%	5.5%	8.7%	28.3%	32.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIIB Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$32.1B	$29.4B	$28.0B	$26.8B	$24.6B	$23.9B	$24.6B	$27.2B	$25.3B	$23.7B	$22.9B	$19.5B	$14.3B	$11.9B	$10.1B	$9.1B	$8.1B	$8.6B	$8.5B	$8.6B	$8.6B
Cash & Cash Equivalents	$1.3B	$3.0B	$2.4B	$1.1B	$3.4B	$2.3B	$1.3B	$2.9B	$1.2B	$1.6B	$2.3B	$1.3B	$1.2B	$603M	$571M	$515M	$760M	$582M	$622M	$660M	$661M
Total Liabilities	$13.2B	$11.2B	$11.3B	$12.0B	$11.2B	$12.9B	$13.9B	$13.9B	$12.3B	$11.1B	$10.7B	$10.1B	$3.5B	$3.2B	$3.2B	$2.6B	$2.6B	$2.3B	$2.7B	$3.1B	$1.4B
Total Debt (Short + Long-Term)	$8.1B	$6.4B	$6.3B	$6.9B	$6.5B	$7.3B	$7.6B	$6.0B	$5.9B	$5.9B	$6.5B	$6.5B	$585M	$596M	$1.1B	$1.1B	$1.2B	$1.1B	$1.1B	$1.6B	$97M
Total Shareholders' Equity	$18.8B	$18.3B	$16.7B	$14.8B	$13.4B	$10.9B	$10.7B	$13.3B	$13.0B	$12.6B	$12.1B	$9.4B	$10.8B	$8.6B	$7.0B	$6.4B	$5.4B	$6.2B	$5.8B	$5.5B	$7.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIIB viewer.

BIIB Metric Deep Dives

Other Companies in Biotechnology

ZOTA · Zota Health Care Limited — ₹40 billion
1530 · 3SBio Inc. — HK$39 billion
3696 · InSilico Medicine Cayman TopCo — HK$35 billion
2696 · Shanghai Henlius Biotech, Inc. — HK$33 billion
2315 · Biocytogen Pharmaceuticals (Beijing) Co., Ltd. — HK$27 billion
DCAL · Dishman Carbogen Amcis Limited — ₹27 billion
9969 · InnoCare Pharma Limited — HK$26 billion
INCY · Incyte — $25 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← BIGY All “B” companies BIII →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.